PHARMACEUTICAL PREPARATION CONTAINING PURIFIED FIBRONECTIN

Abstract: Disclosed are readily reconstitutible lyophilized fibronec­ tin formulations containing fibronectin, a neutral salt, a carbo­ hydrate and a surface active agent.

Description: PHARMACEUTICAL PREPARATION CONTAINING PURIFIED FIBRONECTIN This invention relates to a stable pharmaceutical composition containing fibronectin. More particularly, the invention relates to a stable freeze-dried solid composition containing fibronectin which can be readily reconsitituted. Fibronectin is a large complex protein possessing important biological activities as a structural component of tissues and as a protein modulating and controlling the function of cells in the body in ways that range from normal growth to repair of damage and participation in the defense against invading foreign substances and organisms. It is known by a variety of names that reflect its diverse biological activities including the names of: large external transformation sensitive protein (LETS); cell surface protein (CSP); cell adhesion protein (CAP); opsonic surface binding glycoprotein; and cold insoluble globulin (CIG). Pharmacological application of fibronectin includes treatment of septic shock and treatment of infective diseases. Due to its action of enhancing intercellular adhesive properties and its effect on the morphology of cancer cells, fibronectin is a potential candidate for cancer treatment. Fibronectin is obtained from fractions of plasma protein or fibroblast culture fluid, purified and pasteurized to eliminate the risk of contamination by viruses, and formulated for clinical application. To be suitable for clinical application, fibronectin must be in a readily injectible or infusable form, must possess a high degree of therapeutic activity, must be stable on storage prior to use and must be homogeneous at the time of injection without aggregated particles or precipitates therein. Purified fibronectin obtained by many techniques of purification common to the art is unstable in liquid media, undergoing progressive molecular decomposition on prolonged storage unless it is stored in the frozen state. The decomposition is accelerated by room and elevated temperatures resulting in hydrolysis and formulation into discrete fragments of the polypeptide structure. The loss of therapeutic activity due to decomposition is substantial even within a few weeks rendering the composition ineffective for the intended purpose. Instability may be due to the presence of trace quantities of a proteolytic enzyme which may not be completely removed in the purification of the fibronectin. To stabilize fibronectin and prevent loss of therapeutic activity therein, fibronectin preparations are lyophilized for storage and reconsitituted prior to injection or infusion into the patient. While lyophilization has been found effective in preventing the undesirable decomposition, it created a problem with reconstitution: fibronectin at low temperatures precipitates, hence the name cold insoluble globulin, and on reconstitution in aqueous media a portion of fibronectin remains precipitated requiring extented time periods for dissolution. This is undesirable to both patient and personnel administering the fibronectin, since time is of considerable importance for proper treatment of various conditions. Also, it is left to chance that health care personnel will uniformly insure complete dissolution of fibronectin in each vial containing unit dosages prior to administration to patients. It is known to use stabilizing agents in protein preparations in order to prevent denaturation or other alteration of the proteins. Such stabilizers include albumin, amino acids, gelatin, glycine, and various sugars. It is also known that some of these stabilizing agents enhance the solubility and help prevent aggregation of some freeze dried proteins upon reconstitution. While such stabilizing agents are used to advantage in certain protein formulations, they do not always lend a solution to the problems associated with freeze dried fibronectin preparations, namely, problems of stability, therapeutic activity and reconstitution. The present invention relates to a lyophilized fibronectin preparation containing: 1 - 16 mg/ml fibronectin; 2% to 10% w/v of a carbohydrate; and 0.01% to 0.4% w/v of a pharmaceutically acceptable surface active agent, and in the form of an aqueous solution for intravenous administration. The present invention also relates to an aqueous fibronectin solution for lyophilization containing said components. In accordance with the present invention a preparation is made containing: an aqueous solution of fibronectin; a carbohydrate; and a surface active agent. Additionally, a neutral salt such as sodium chloride is added to adjust osmolar concentration and a buffer salt is used to control pH of the media. The preferred buffer salt is sodium citrate, which in small quantities enhances solubility of fibronectin and also possesses mild chelating properties helping to prevent fibronectin polymerization. In general, the purified and pasteurized fibronectin in an aqueous solution containing the above-described ingredients is lyophilized into a solid in suitable containers and stored. Prior to use, the solid is reconstituted with sterile water. The active component of the formulations of the present invention in an aqueous solution is purified and pasteurized fibronectin comprising about 85 to 100% of the dissolved proteinaceous solids which can be obtained from human plasma, cryoprecipitate fraction of human plasma, a sub-fraction of the cryoprecipitate of human plasma, and Fraction I and Fraction I-O of human plasma. The procedure for obtaining the purified fibronectin may be any of the procedures used by the prior art that result in such purification. The purified and pasteurized fibronectin so obtained is present in an aqueous solution containing about 1 to about 16 mg/ml and preferably about 3 to about 8 mg/ml of fibronectin. Generally, such aqueous solutions also contain a buffer and/or neutral salt in sufficient quantities to maintain solubility of fibronectin and to regulate the pH from about 6 to 8, preferably from about 6.5 to 7.5 and most preferably from 6.8 to 7.3. In practicing the present invention it is desirable to so design the final steps of the purification and pasteurizaation of fibronectin that the ingredients used therein are the same as, or are compatible with, the ingredients of the formulations of the present invention. This desired result may also be accomplished by exchange or removal of certain components, such as buffer or neutral salts by the technique of dialysis across a semi-permeable membrane or diafiltration. Alternatively, permeation chromatography technique on hydrophilic gel media, such as cross-linked dextran, agarose, or polyacrylamide may be employed for removal of certain components from the fibronectin solution. As previously noted, highly purified solutions of fibronectin in which fibronectin comprises about 85 to 100% and preferably at least 95% of the dissolved proteinaceous solids undergo molecular decomposition on extended storage in liquid media. The decomposition is progressive with time and is accelerated by room and elevated temperatures. While the mechanism of decomposition is not well understood, the resultant preparation containing fragments of fibronectin is not well-suited for clinical use. Lyophilization on the other hand, prevents such decomposition and is therefore an effective means for preserving the biological properties of fibronectin. Table I illustrates the typical result obtained on analysis of the respective solutions. TABLE I Decomposition of Fibronectin with Time at 200C. After After After 1 Wk. 1 Mo. 3 Mos. Aqueous solution of fibronectin 5% 30% 100% Lyophilized fibronectin 0 0 0 It can be readily ascertained from the above results that lyophilization prevents decomposition of fibronectin on storage. However, upon trying to reconstitute the lyophilized fibronectin great difficulty was experienced withzthe dissolution of fibronectin as shown in the following examples. EXAMPLE 1 Compositions of fibronectin (fun) containing 189 mg of fibronectin, in a buffer of 0.13 M Narc1, 0.05 M glycine sodium glycinate, 0.01 M Sodium citrate, at pH 7.3, having amounts of albumin indicated herein were lyophilized and then reconstituted with 50 ml of water. Percent dissolution of fibronectin at various time intervals are shown. The amount of fibronectin dissolved was determined by absorbance measurement at 280 nm using an A280 of 12.8 for 1% (w/v) fibronectin solution. Albumin Time in minutes after Recon. % of Fn in Solution 0 15 53.3 30 63.1 60 64.7 1440 82.2 2 mg/ml 15 59.2 30 76.4 60 82.0 1440 105.0 5 mg/ml 15 64.5 30 75.6 60 78.5 1440 90.2 10 mg/ml 15 69.0 30 79.3 60 82.5 1440 95.5 20 mg/ml 15 73.2 30 78.0 60 78.2 1440 89.0 Without albumin, even after 1440 minutes, only 82.2% of the fibronectin is dissolved. Although albumin enhances dissolution of fibronectin, the indicated time intervals for dissolution are too long to be of practical value. EXAMPLE 2 Compositions of fibronectin containing 189 mg of fibronectin, in a buffer of 0.08 M NaCl, 0.01 M citrate, at pH 7.3, having 2.5% w/v sucrose and amounts of albumin indicated herein were lyophilized and then reconsitituted with 50 ml of water. Percent dissolution of fibronectin at various time intervals are shown. The amount of fibronectin dissolved was determined as in Example 1. Albumin Time in minutes after Recon. % of Fn in Solution 0 15 47.7 30 47.7 60 48.8 1440 73.0 2 mg/ml 15 87. 8 30 93.1 60 94.4 1440 105.0 5 mg/ml 15 79.8 30 85.1 60 85.9 1440 100.9 10 mg/ml 15 82.0 30 90.5 60 90.7 1440 108.6 26 mg/ml 15 83.0 30 90.5 60 92.0 1440 105.0 With albumin and sucrose present there appears to be certain improvement in enhancement of dissolution, however, the required dissolution time is still impractical. EXAMPLE 3 Compositions of fibronectin containing 125 mg of fibronectin, in a buffer of 0.075 M Nail, 0.002 M citrate, at pH 7.2, having amounts of surfactant Tween80 indicated herein were lyophilized and then reconstituted with 25 ml of water. Percent dissolution of fibronectin at various time intervals are shown. The amount of fibronectin dissolved was determined as in Example 1. z of Tween@80 Time in minutes after Recon. % of Fn in Solution 0.02 15 48.4 30 57.8 60 75.8 0.05 15 49.2 30 66.4 60 82.0 0.10 15 58.6 30 70.4 60 83.6 0.20 15 47.6 30 58.6 60 81.2 The surfactant used in this example is not effective in enhancing dissolution of fibronectin. EXAMPLE 4 Compositions of fibronectin containing 189 mg of fibronectin, in a buffer of 0.08 M NaCl, 0.01 M citrate at pH 7.3, having 2.5% w/v glucose and amounts of the surfactant Pluronic F68 indicated herein were lyophilized and then reconstituted with 50 ml of water. Percent dissolution of fibronectin at various time intervals are shown. The amount of fibronectin dissolved was determined as in Example 1. 9 of Pluronic F68 Time in min. after r;econ, % of Fn in Solution 0.02 15 84.9 30 79.8 60 79.3 1440 103.3 0.05 15 103.2 30 105.6 60 107.2 1440 126.1 0.10 15 68.7 30 67.4 60 67.1 1440 82.8 0.40 15 93.2 30 98.5 60 99.4 1440 103.0 Dissolution of fibronectin in the presence of Pluronic F68 and glucose is enhanced. We have discovered that selected ingredients used in lyophilized formulations containing fibronectin enables full and complete solution of fibronectin in a short period of time, ranging from a couple to 20 minutes, preferably to less than 10 minutes, and most preferably to less than one minute. The reconstituted solution of fibronectin prepared in accordance with the present invention is safe and effective and may be injected or infused into patients in need of fibronectin. L A preferred embodiment of the invention comprises: a., an aqueous solution containing about 1-16 mg/ml, preferably about 3-8 mg/ml, and most preferably about 46 mg/ml of fibronectin; b., a 0.002M to 0.05M, preferably 0.005M to 0.02M of a physiologically acceptable buffer salt selected from the group consisting of sodium citrate, sodium glycinate, sodium phosphate, and tris (hydr:ymethyl) aminomethane or mixtures thereof; c., c., a 0.03M to 0..09M, and preferably 0.04 to 0.08M of a neutral salt, such as sodium chloride, to adjust the osmolar concentration of the formula to that of the physiologic milieu of about 0.14M of sodium chloride. d., about 2% to 10% w/v, and preferably about 3% to 7% w/v of a carbohydrate selected from the group con sisting of monosaccharides and disaccharides including glu cose, galactose, mannose, sucrose, lactose, maltose, mannitol, or sorbitol; and e., about 0.01% to 0.4% w/v, preferably 0.02% to 0.1% w/v of a pharmaceutically acceptable surface active agent selected from the group consisting of: poly (oxyakly lenes) mono- and tri-sorbitan esters (fatty acid esters of sorbitol and its anhydrides copolymerized with a varying number of moles of ethylene oxide) such as Polysorbate 80 (an oleate ester), Polysorbate 20 (a laurate ester), Poly sorbate 40 (a palmitate ester), and Polysorbate 60 (a stearate ester); alkyl phenyl polyoxyethylenes (such as Tritons and NomidetX ); anionic agents such as bile salts (sodium taurocholate, sodium cholate, sodium deoxycholate and sodium glycocholate); and polyhydric alcohols with surface active properties such as the high molecular weight copolymers of propylene glycol and propylene oxide sold under the trade names of Pluronice F-38 and PluronicX F-68. The above described ingredients are admixed and the pH of the mixture is adjusted, using an acid or a base, to the value of 6.5 - 7.5 and preferably 6.8 - 7.3. The mixture is then lyophilized in suitable containers for storage. The following examples illustrate the preparations of the present invention. EXAMPLE 5 To 13 liters of an aqueous solution containing about 7 mg/ml of fibronectin, 0.01M sodium citrate and 0.075M NaCl at pH 6.7 was added 0.5 Kg of parental grade glucose and 10 grams of Polysorbate 80 (PS 80). The solution was gently stirrred until all components dissolved. The solution was then diluted to 20 liters with an aqueous buffer consisting of 0.01M sodium citrate, 0.075M NaC1 at about pH 7.0. The pH of the resultant solution was verified to be between 6.8 - 7.3, then the solution was subjected to initial clarification on a non-sterile filter and then sterilized by passage through a sterile, bacterially retentive filter. The sterile solution was then asceptically dispensed into glass vials, 50 ml per vial, fitted with an appropriate rubber stopper of the lyophilizing type. The vials wee placed in a freezer, and after freezing, subjected to lyophilization by the procedure customarily used in the art. EXAMPLE 6 To about 14 liters of an aqueous solution containing about 8.2 mg/ml of fibronectin, 6% w/v of sucrose, 0.005M sodium citrate, 0.005M sodium glycinate at a pH of 6.5 was added 135 gms of NaCl, and 7.5 gms of Polysorbate 80. After dissolution of the ingredients by stirring, the volume was adjusted to 15 liters with an aqueous buffer solution of 0.005M of sodium citrate and 0.005M of sodium glycinate at pH 7.2. The pH of the diluted solution was adjusted with dilute HC1 and NaOH and was verified to be between 6.8 7.3. The solution was then further processed as described in Example 5. EXAMPLE 7 Eight liters of an aqueous solution containing 7.6 mg/ml of purifed fibronectin, 0. OOlM sodium citrate, and 0.16M NaCI at pH 7.0 was diluted two-fold with an aqueous buffer consisting of 0.01M sodium citrate, 5.0% w/v glucose and 8 grams of PluronicF-68 at pH 7.0. After stirring to obtain complete dissolution the pH of the resultant solution was between 6.8 - 7.3. The solution was then further processed as described in Example 5. EXAMPLE 8 An aqueous solution of 12 mg/ml fibronectin was obtained containing 8M urea and 0.01M sodium citrate at pH 7.2 from a commercial source. The solution was processed over a chromatographic column of Sephaaex-G-25 equilibrated with an aqueous buffer solution containing 5.0% w/v sucrose, 0.05M NaCl, and 0.02M sodium citrate at pH 7.0. During chromatographic equilibration of two 3 liter batches of purified fibronectin on a column bed of 16 liters the fibronectin was diluted from the initial concentration of 12 mg/ml to about 8 mg/ml. The two batches of purified fibronectin were then pooled. Nine liters of this pooled solution was further diluted with additional column buffer to obtain a fibronectin concentration of about 6 mg/ml. To 12 liters of the diluted solution was added with stirring 6.0 gms of Polysorbate 80. The pH of the resultant solution was between 6.8 - 7.3. The solution was further processed as described in Example 5. EXAMPLE 9 To 5 liters of an aqueous solution containing 6.3 mg/ml purified fibronectin, 0.075M NaCl, 0.002M sodium citrate at pH 7.2 was 0.325 Kg of parenteral grade maltose and 5.0 gms of Polysorbate-80. The ingredients were dissolved by gentle stirring. The solution was diluted to about 6.5 liters with an aqueous solution containing 0.01M sodium citrate, 0.075M NaCl at pH 7.0. The pH of the resultant solution was adjusted to 6.8 - 7.3 using dilute HC1 and NaOH. The solution was further processed as described in Example 5. EXAMPLE 10 To 6.3 liters of an aqueous solution containing 8.1 mg/ml of purified fibronectin, 0.002M sodium citrate and 0.05M NaCl at pH 7.2 was added 0.5 Xg of parenteral grade sucrose and 5 grams of sodium taurocholate. After mixing to dissolve the ingredients, the volume was adjusted to 10.0 liters with an aqueous solution containing 0.05M NaCl and 0.002M sodium citrate at pH 7.2. The solution was then further processed as described in Example 5, EXAMPLE 11 To 5 liters of an aqueous solution containing 6.2 mg/ml of purified fibronectin, 0.002M sodium citrate and 0.05M NaCl at pH 7.1 was added 0.30 Kg of parenteral grade sucrose and 3.07gms of PluronicX F-68. The solution was mixed to dissolve the ingredients and the volume was adjusted to 6.1 liters with an aqueous solution containing O.05M NaCl and 0.002M sodium citrate at pH 7.1. The pH of the solution was adjusted to 6.8 - 7.3 using dilute HCl and NaOH. The solution was then further processed as described is Example 5. Compositions of the final formulas are presented in Table II. TABLE II FORMULAS 5 6 7 8 9 10 11 Fibronectin 4.5mg/ml 7.6mg/ml 3. & gIm1 5.5mg/ml 5.1mg/ml 5.1mg/ml 5.1mg/ml Buffer salt 0.0L H 0.005 H 0.01 M 0.02 H- 0.002 H 0.002 X 0.002 H Citrate Citrate 0.005 H Citrate Citrate Citrate Citrate Citrate Glycine Neutral Salt (NaCl) 0.075 M .075 H 0.08 H 0.05 M 0.075 H 0.05 M 0.05 EE Carbohydrate 2.5% 5.0% 5.0Z .5.0% 5.0Z 5.0Z 5.0X Glucose Sucrose Glucose Sucrose Maltase Sucrose Sucrose Surfactant PS-80 1580 Pluronic# PS-80 PS-80 Tauro- Pluronic p-68 Cbolate F-68 0.05% 0.05% 0.05Z 0.10X 0.05Z 0.05Z 0.02. The following example describes the dosage form for human administration. EXAMPLE 12 Quantitative Composition of Human Fibronectin Ingredient Amount per Container Fibronectin, Human 202.5 mq - 275 mg Sucrose 2.5 gm + 0.25 Sodium Chloride 0.146 gm + 0,015 Polysorbate 80 0.025 gm i 0.003 Sodium Citrate 0.028 gm + 0.003 Water For Injection 50 ml* * Removed during lyophilization The lyophilized formulations of the present invention are easily reconstituted prior to use. Illustrative data on reconstitution is presented in Example 13. EXAMPLE 13 Fibronectin lyophilized in the presence of 0.075M NaCI, 0.002M sodium citrate and containing the herein denoted amounts of carbohydrates and surfactants were reconstituted with 48.5 ml of water. Reconstitution time and remarks are shown hereinbelow. Carbohydrate Surfactant Recon. Time Remarks 5% sucrose - A large clump floating, 79% soluble after 60 min. 5% sucrose 0.05% Tween80 3 min. 45 sec. Clear no particulate 5% sucrose 0.05% Pluronic 5 min. 15 sec. Clear F68 no particulate 5% sucrose 0.05% 6 min. 45 sec. Clear Taurocholate no particulate 2.5% glucose - - A large clump floating, 90% soluble after 60 min. 2.5 glucose 0.05% Tween 80 16min. 30sec. A few very small particles. 2.5% glucose 0.05% PluronicX 10 min. 15 sec. A few very small F68 particles 2.5% glucose 0.05% 34 min. 30 sec. A few very small Taurocholate particles The results in Example 13 clearly show the unexpected and greatly improved solubility within short time periods of the lyophilized fibronectin in the formulations of the present invention.

Claims: WHAT IS CLAIMED IS: 1. A lyophilized fibronectin preparation containing: I - 16 mg/ml fibronectin; 2% to 10% w/v of a carbohydrate; and 0.01% to 0.4e w/v of a pharmaceutically acceptable surface active agent. 2. The preparation of claim 1 further containing 0.03M to 0.09M of a neutral salt. 3. The preparation of claim 2 wherein the neutral salt is sodium chloride. 4. The preparation of claim 1 further containing 0.002M to 0.05M of a physiologically acceptable buffer salt. 5. The preparation of any of claims 1 to 4 wherein the buffer salt is sodium citrate, sodium glycinate, sodium phosphate, tris(hydroxymethyl)aminomethane, or mixtures thereof. 6. The preparation of any of claims 1 to 5 wherein the carbohydrate is a monosaccharide or disaccharide. 7. The preparation of any of claims 1 to 5 wherein the carbohydrate is glucose, galactose, mannose, sucrose, lactose, maltose, mannitol, or sorbitol. 8. The preparation of any of claims 1 to 7 wherein the surface active agent is: polyoxy ethylene sorbitan monoand tri-esters; alkyl phenyl polyoxyethylenes; sodium taurocholate, sodium cholate, sodium deoxycholate, sodium glycocholate; or polyhydric alcohols. 9. The preparation of claim 8 wherein the polyoxy ethylene sorbitan ester contains the fatty acid oleate, laurate, stearate or palmitate. 10. The preparation of any of claims 1 to 9 wherein the preparation is reconstituted with sterile water. 11. The preparation of any of claims 1 to 8 wherein the preparation contains on reconstitution with sterile water: 1 - 16 mg/ml of fibronectin; 0.002M to 0.05M of a physiologically acceptable buffer salt selected from sodium citrate, sodium glycinate, sodium phosphate or tris(hydroxymethyl)amino methane; 0.03M to 0.09M of sodium chloride; about 2% to 10% w/v of a carbohydrate selected from glucose, galactose, mannose, sucrose, lactose, maltose, mannitol or sorbitol; 0.01% to 0.4% w/v of a pharmaceutically acceptable surface active agent selected from polyoxy ethylene sorbitan mono- and tri- esters; alkyl phenyl polyoxyethylenes; sodium taurocholate, sodium cholate, sodium deoxycholate, sodium glycocholate; or polyhydric alcohols. 12. The preparation of claims 1 to 8 wherein the preparation contains a reconstitution with sterile water: 3 - 8 mg/ml fibronectin; 0.005M to 0.02M of a physiologically acceptable salt selected from sodium citrate, sodium glycinate, sodium phosphate or hydroxy amino methane; 0.04M to 0.08M of sodium chloride; 3% to 7% w/v of a carbohydrate selected from glucose, galactose, mannose, sucrose, lactose, maltose, mannitol, or sorbitol; 0.02% w/v to 0.1% w/v of a pharmaceutically acceptable surface active agent selected from polyoxy ethylene sorbitan mono- and tri- esters; alkyl phenyl polyoxyethylenes; sodium taurocholate, sodium cholate, sodium deoxycholate, sodium glycocholate; or polyhydric alcohols. 13. The preparation of any of claims 10 to 12 wherein the preparation has a pH of 6.5 to 7.5. 14. An aqueous fibronectin solution for lyophilization containing the components set forth in any of claims 1 to 9. 15. The fibronectin solution of claim 11 wherein said carbohydrate is selected from the group consisting of monosaccarides and disaccharides. 16. The fibronectin solution of claim 11 wherein said carbohydrate is selected from the group consisting of glucose, galactose, mannose, sucrose, lactose, maltose, mannitol, and sorbitol. 17. The fibronectin solution of claim 11 wherein said surface active agent is selected from the group consisting of: polyoxy ethylene sorbitan mono- and tri- esters; alkyl phenyl polyoxethylenes; sodium taurocholate, sodium cholate, sodium deoxycholate, sodium glycocholate; and polyhydric alcohols. 18. The fibronectin solution of claim 17 wherein said polyoxy ethylene sorbitan ester contains the fatty acid oleate, laurate, stearate and palmitate. 19. A lyophilized fibronectin preparation readily reconstitutable with sterile water comprising on reconstitution: 1 - 16 mg/ml of fibronectin; 0.002M to 0.05M of a physiologically acceptable buffer salt selected from sodium citrate, sodium glycinate, sodium phosphate or tris(hydroxymethyl)amino methane; 0.03M to 0.09M of sodium chloride; about 2% to 10% w/v of a carbohydrate selected from glucose, galactose, mannose, sucrose, lactose, maltose, mannitol or sorbitol; 0.01% to 0.4% w/v of a pharmaceutically acceptable surface active agent selected from polyoxy ethylene sorbitan mono- and tri- esters; alkyl phenyl polyoxyethylenes; sodium taurocholate, sodium cholate, sodium deoxycholate, sodium glycocholate; or polyhydric alcohols. 20. The lyophilized fibronectin preparation of claim 19 wherein said polyoxy ethylene sorbitan ester contains the fatty acid oleate, laurate, stearate and palmitate. 21. The fibronectin preparation of claim 19 having a pH of 6.5 to 7.5. 22. The fibronectin preparation of claim 19 wherein said lyophilized fibronectin is reconstituted into an aqueous solution within 20 minutes. 23. A lyophilized fibronectin preparation reconstitutable in 10 minutes with sterile water comprising on reconstitution: 3 - 8 mg/ml fibronectin; 0.005M to 0.02M of a physiologically acceptable salt selected from sodium citrate, sodium glycinate, sodium phosphate or hydroxy amino methane; 0.04M to 0.08M of sodium chloride; 3% to 7% w/v of a carbohydrate selected from glucose, galactose, mannose, sucrose, lactose, maltose, mannitol, or sorbitol; 0.02% w/v to 0.1% w/v of a pharmaceutically acceptable surface active agent selected from polyoxy ethylene sorbitan mono- and tri- esters; alkyl phenyl polyoxyethylenes; sodium taurocholate, sodium cholate, sodium deoxycholate, sodium glycocholate; or polyhydric alcohols.

Inventors: FARB, DAVID L., LANDABURU, RICARDO H., VIOLAND, BERNARD N., YUE, ROBERT H.
Applicants: ARMOUR PHARMACEUTICAL COMPANY
Application year: 1984
Main classification: A61K37
IPC codes: A61K47, A61K9, A61K38